{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:47:36Z","timestamp":1789123656769,"version":"build-2803163510"},"reference-count":249,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Talent Introduction Project of Zhejiang Shuren University","award":["KXJ1723105"],"award-info":[{"award-number":["KXJ1723105"]}]},{"name":"Zhejiang Shuren University Basic Scientific Research Special Funds","award":["KXJ1724104C and 2024XZ013"],"award-info":[{"award-number":["KXJ1724104C and 2024XZ013"]}]},{"name":"The opening foundation of the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine","award":["KXJ1724104C and 2024XZ013"],"award-info":[{"award-number":["KXJ1724104C and 2024XZ013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04523-1","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:34:01Z","timestamp":1770122041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular mechanisms of Epstein-Barr Virus in the pathogenesis of lymphomas and new opportunities for precision medicine"],"prefix":"10.1007","volume":"17","author":[{"given":"Hanlin","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoyan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minting","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"4523_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","volume":"102","author":"SK Dunmire","year":"2018","unstructured":"Dunmire SK, Verghese PS, Balfour HH Jr. Primary epstein-barr virus infection. J Clin Virol. 2018;102:84\u201392.","journal-title":"J Clin Virol"},{"issue":"1","key":"4523_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1386-6532(01)00149-4","volume":"21","author":"KH Chan","year":"2001","unstructured":"Chan KH, Tam JS, Peiris JS, Seto WH, Ng MH. Epstein-Barr virus (EBV) infection in infancy. J Clin Virol. 2001;21(1):57\u201362.","journal-title":"J Clin Virol"},{"issue":"1","key":"4523_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1128\/jb.92.1.269-271.1966","volume":"92","author":"W Henle","year":"1966","unstructured":"Henle W, Hummeler K, Henle G. Antibody coating and agglutination of virus particles separated from the EB3 line of Burkitt lymphoma cells. J Bacteriol. 1966;92(1):269\u201371.","journal-title":"J Bacteriol"},{"issue":"6","key":"4523_CR4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ijc.2910030619","volume":"3","author":"JH Pope","year":"1968","unstructured":"Pope JH, Horne M, Scott W. Transformation of foetal human leukocytes in vitro by filtrates of a human leukaemic cell line containing herpes\u2010like virus. Int J Cancer. 1968;3(6):857\u201366.","journal-title":"Int J Cancer"},{"issue":"2","key":"4523_CR5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/path.4459","volume":"235","author":"M Vockerodt","year":"2015","unstructured":"Vockerodt M, Yap LF, Shannon-Lowe C, Curley H, Wei W, Vrzalikova K, et al. The epstein-barr virus and the pathogenesis of lymphoma. J Pathol. 2015;235(2):312\u201322.","journal-title":"J Pathol"},{"issue":"32","key":"4523_CR6","doi-asserted-by":"publisher","first-page":"16046","DOI":"10.1073\/pnas.1901314116","volume":"116","author":"P Mrozek-Gorska","year":"2019","unstructured":"Mrozek-Gorska P, Buschle A, Pich D, Schwarzmayr T, Fechtner R, Scialdone A, et al. Epstein-barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection. Proc Natl Acad Sci U S A. 2019;116(32):16046\u201355.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4523_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.humpath.2018.05.020","volume":"79","author":"SA Rezk","year":"2018","unstructured":"Rezk SA, Zhao X, Weiss LM. Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update. Hum Pathol. 2018;79:18\u201341.","journal-title":"Hum Pathol"},{"issue":"12","key":"4523_CR8","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1084\/jem.20190678","volume":"216","author":"R Rodriguez","year":"2019","unstructured":"Rodriguez R, Fournier B, Cordeiro DJ, Winter S, Izawa K, Martin E, et al. Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells. J Exp Med. 2019;216(12):2800\u201318.","journal-title":"J Exp Med"},{"key":"4523_CR9","first-page":"94","volume":"80","author":"JP Andersson","year":"1991","unstructured":"Andersson JP. Clinical aspects on epstein-barr virus infection. Scand J Infect Dis Suppl. 1991;80:94\u2013104.","journal-title":"Scand J Infect Dis Suppl"},{"issue":"6769","key":"4523_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503\u201311.","journal-title":"Nature"},{"issue":"23","key":"4523_CR11","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa055759","volume":"354","author":"SS Dave","year":"2006","unstructured":"Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, et al. Molecular diagnosis of Burkitt\u2019s lymphoma. N Engl J Med. 2006;354(23):2431\u201342.","journal-title":"N Engl J Med"},{"issue":"Pt 1","key":"4523_CR12","first-page":"315","volume":"390","author":"JA Healy","year":"2015","unstructured":"Healy JA, Dave SS. The role of EBV in the pathogenesis of diffuse large B cell lymphoma. Curr Top Microbiol Immunol. 2015;390(Pt 1):315\u201337.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"26","key":"4523_CR13","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"14","key":"4523_CR14","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36(14):1428\u201339.","journal-title":"J Clin Oncol"},{"issue":"19","key":"4523_CR15","doi-asserted-by":"publisher","first-page":"7922","DOI":"10.1073\/pnas.1303800110","volume":"110","author":"SK Knutson","year":"2013","unstructured":"Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A. 2013;110(19):7922\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4523_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1056\/NEJMc1111708","volume":"366","author":"L Couronne","year":"2012","unstructured":"Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012;366(1):95\u20136.","journal-title":"N Engl J Med"},{"issue":"3","key":"4523_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/rmv.456","volume":"15","author":"W Amon","year":"2005","unstructured":"Amon W, Farrell PJ. Reactivation of Epstein-Barr virus from latency. Rev Med Virol. 2005;15(3):149\u201356.","journal-title":"Rev Med Virol"},{"issue":"1","key":"4523_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","volume":"14","author":"PJ Farrell","year":"2019","unstructured":"Farrell PJ. Epstein-Barr virus and cancer. Annu Rev Pathol. 2019;14(1):29\u201353.","journal-title":"Annu Rev Pathol"},{"issue":"20","key":"4523_CR19","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania B, Kenney SC, Raab-Traub N. Epstein-Barr virus: biology and clinical disease. Cell. 2022;185(20):3652\u201370.","journal-title":"Cell"},{"issue":"3","key":"4523_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/v15030714","volume":"15","author":"H Yu","year":"2023","unstructured":"Yu H, Robertson ES. Epstein\u2013barr virus history and pathogenesis. Viruses. 2023;15(3):714.","journal-title":"Viruses"},{"issue":"12","key":"4523_CR21","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc.2016.92","volume":"16","author":"LS Young","year":"2016","unstructured":"Young LS, Yap LF, Murray PG. Epstein\u2013barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer. 2016;16(12):789\u2013802.","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"4523_CR22","doi-asserted-by":"publisher","first-page":"7825","DOI":"10.1128\/JVI.00445-07","volume":"81","author":"LM Hutt-Fletcher","year":"2007","unstructured":"Hutt-Fletcher LM. Epstein-barr virus entry. J Virol. 2007;81(15):7825\u201332.","journal-title":"J Virol"},{"issue":"22","key":"4523_CR23","doi-asserted-by":"publisher","first-page":"11217","DOI":"10.1128\/JVI.01673-08","volume":"82","author":"KA Young","year":"2008","unstructured":"Young KA, Herbert AP, Barlow PN, Holers VM, Hannan JP. Molecular basis of the interaction between complement receptor type 2 (CR2\/CD21) and Epstein-barr virus glycoprotein gp350. J Virol. 2008;82(22):11217\u201327.","journal-title":"J Virol"},{"issue":"24","key":"4523_CR24","doi-asserted-by":"publisher","first-page":"13214","DOI":"10.1128\/JVI.05580-11","volume":"85","author":"LS Chesnokova","year":"2011","unstructured":"Chesnokova LS, Hutt-Fletcher LM. Fusion of Epstein-barr virus with epithelial cells can be triggered by \u03b1v\u03b25 in addition to \u03b1v\u03b26 and \u03b1v\u03b28, and integrin binding triggers a conformational change in glycoproteins gHgL. J Virol. 2011;85(24):13214\u201323.","journal-title":"J Virol"},{"issue":"2","key":"4523_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1097-2765(02)00465-3","volume":"9","author":"MM Mullen","year":"2002","unstructured":"Mullen MM, Haan KM, Longnecker R, Jardetzky TS. Structure of the Epstein-barr virus gp42 protein bound to the MHC class II receptor HLA-DR1. Mol Cell. 2002;9(2):375\u201385.","journal-title":"Mol Cell"},{"issue":"5","key":"4523_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16050991","volume":"16","author":"AS Torne","year":"2024","unstructured":"Torne AS, Robertson ES. Epigenetic mechanisms in latent Epstein-barr virus infection and associated cancers. Cancers. 2024;16(5):991.","journal-title":"Cancers"},{"key":"4523_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.coviro.2013.12.001","volume":"4","author":"C Shannon-Lowe","year":"2014","unstructured":"Shannon-Lowe C, Rowe M. Epstein barr virus entry; kissing and conjugation. Curr Opin Virol. 2014;4:78\u201384.","journal-title":"Curr Opin Virol"},{"issue":"1","key":"4523_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/35095584","volume":"1","author":"DA Thorley-Lawson","year":"2001","unstructured":"Thorley-Lawson DA. Epstein-barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1(1):75\u201382.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"4523_CR29","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/femsre\/fuz023","volume":"43","author":"J Chen","year":"2019","unstructured":"Chen J, Longnecker R. Epithelial cell infection by Epstein-barr virus. FEMS Microbiol Rev. 2019;43(6):674\u201383.","journal-title":"FEMS Microbiol Rev"},{"issue":"8","key":"4523_CR30","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1128\/jvi.64.8.3753-3759.1990","volume":"64","author":"EA Holley-Guthrie","year":"1990","unstructured":"Holley-Guthrie EA, Quinlivan EB, Mar E-C, Kenney S. The Epstein-barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J Virol. 1990;64(8):3753\u20139.","journal-title":"J Virol"},{"issue":"6","key":"4523_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061479","volume":"12","author":"D Germini","year":"2020","unstructured":"Germini D, Sall FB, Shmakova A, Wiels J, Dokudovskaya S, Drouet E, et al. Oncogenic properties of the EBV ZEBRA protein. Cancers (Basel). 2020;12(6):1479.","journal-title":"Cancers (Basel)"},{"issue":"14","key":"4523_CR32","doi-asserted-by":"publisher","first-page":"7634","DOI":"10.1128\/JVI.78.14.7634-7644.2004","volume":"78","author":"AS El-Guindy","year":"2004","unstructured":"El-Guindy AS, Miller G. Phosphorylation of Epstein-Barr virus ZEBRA protein at its casein kinase 2 sites mediates its ability to repress activation of a viral lytic cycle late gene by Rta. J Virol. 2004;78(14):7634\u201344.","journal-title":"J Virol"},{"issue":"11","key":"4523_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00428-20","volume":"94","author":"NA Smith","year":"2020","unstructured":"Smith NA, Coleman CB, Gewurz BE, Rochford R. CD21 (complement receptor 2) is the receptor for Epstein-Barr virus entry into T cells. J Virol. 2020;94(11):e00428-00420.","journal-title":"J Virol"},{"issue":"2","key":"4523_CR34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0092-8674(87)90216-9","volume":"50","author":"J Tanner","year":"1987","unstructured":"Tanner J, Weis J, Fearon D, Whang Y, Kieff E. Epstein-Barr virus gp350\/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell. 1987;50(2):203\u201313.","journal-title":"Cell"},{"issue":"19","key":"4523_CR35","doi-asserted-by":"publisher","first-page":"10179","DOI":"10.1128\/JVI.77.19.10179-10185.2003","volume":"77","author":"PG Spear","year":"2003","unstructured":"Spear PG, Longnecker R. Herpesvirus entry: an update. J Virol. 2003;77(19):10179\u201385.","journal-title":"J Virol"},{"issue":"5","key":"4523_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nrmicro2548","volume":"9","author":"SA Connolly","year":"2011","unstructured":"Connolly SA, Jackson JO, Jardetzky TS, Longnecker R. Fusing structure and function: a structural view of the herpesvirus entry machinery. Nat Rev Microbiol. 2011;9(5):369\u201381.","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"4523_CR37","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/rmv.1780","volume":"24","author":"T Murata","year":"2014","unstructured":"Murata T, Tsurumi T. Switching of EBV cycles between latent and lytic states. Rev Med Virol. 2014;24(3):142\u201353.","journal-title":"Rev Med Virol"},{"issue":"3","key":"4523_CR38","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1074-7613(00)80622-6","volume":"9","author":"GJ Babcock","year":"1998","unstructured":"Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity. 1998;9(3):395\u2013404.","journal-title":"Immunity"},{"issue":"1","key":"4523_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2014.84","volume":"47","author":"MS Kang","year":"2015","unstructured":"Kang MS, Kieff E. Epstein-Barr virus latent genes. Exp Mol Med. 2015;47(1):e131.","journal-title":"Exp Mol Med"},{"issue":"5","key":"4523_CR40","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/mp.53.5.238","volume":"53","author":"LS Young","year":"2000","unstructured":"Young LS, Dawson CW, Eliopoulos AG. The expression and function of Epstein-Barr virus encoded latent genes. Mol Pathol. 2000;53(5):238\u201347.","journal-title":"Mol Pathol"},{"issue":"6","key":"4523_CR41","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1128\/jvi.66.6.3409-3414.1992","volume":"66","author":"N Miller","year":"1992","unstructured":"Miller N, Hutt-Fletcher LM. Epstein-Barr virus enters B cells and epithelial cells by different routes. J Virol. 1992;66(6):3409\u201314.","journal-title":"J Virol"},{"issue":"1","key":"4523_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7240","volume":"6","author":"H-B Wang","year":"2015","unstructured":"Wang H-B, Zhang H, Zhang J-P, Li Y, Zhao B, Feng G-K, et al. Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells. Nat Commun. 2015;6(1):6240.","journal-title":"Nat Commun"},{"key":"4523_CR43","first-page":"137","volume-title":"Seminars in cancer biology","author":"SW Tsao","year":"2012","unstructured":"Tsao SW, Tsang CM, Pang PS, Zhang G, Chen H, Lo KW. The biology of EBV infection in human epithelial cells. In: Tsao SW, Tsang CM, Pang PS, Zhang G, editors. Seminars in cancer biology. Amsterdam: Elsevier; 2012. p. 137\u201343."},{"issue":"11","key":"4523_CR44","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/nsmb1161","volume":"13","author":"G Szakonyi","year":"2006","unstructured":"Szakonyi G, Klein MG, Hannan JP, Young KA, Ma RZ, Asokan R, et al. Structure of the Epstein-Barr virus major envelope glycoprotein. Nat Struct Mol Biol. 2006;13(11):996\u20131001.","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"4523_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms7060183","volume":"7","author":"S Jangra","year":"2019","unstructured":"Jangra S, Yuen KS, Botelho MG, Jin DY. Epstein-Barr virus and innate immunity: friends or foes? Microorganisms. 2019;7(6):183.","journal-title":"Microorganisms"},{"issue":"2","key":"4523_CR46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.sbi.2009.02.012","volume":"19","author":"M Backovic","year":"2009","unstructured":"Backovic M, Jardetzky TS. Class III viral membrane fusion proteins. Curr Opin Struct Biol. 2009;19(2):189\u201396.","journal-title":"Curr Opin Struct Biol"},{"issue":"5","key":"4523_CR47","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0969-2126(02)00759-1","volume":"10","author":"EJ Sundberg","year":"2002","unstructured":"Sundberg EJ, Li H, Llera AS, McCormick JK, Tormo J, Schlievert PM, et al. Structures of two streptococcal superantigens bound to TCR beta chains reveal diversity in the architecture of T cell signaling complexes. Structure. 2002;10(5):687\u201399.","journal-title":"Structure"},{"issue":"5","key":"4523_CR48","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jmb.2006.08.012","volume":"362","author":"HE Gilbert","year":"2006","unstructured":"Gilbert HE, Asokan R, Holers VM, Perkins SJ. The 15 SCR flexible extracellular domains of human complement receptor type 2 can mediate multiple ligand and antigen interactions. J Mol Biol. 2006;362(5):1132\u201347.","journal-title":"J Mol Biol"},{"issue":"52","key":"4523_CR49","doi-asserted-by":"publisher","first-page":"22641","DOI":"10.1073\/pnas.1011806108","volume":"107","author":"H Matsuura","year":"2010","unstructured":"Matsuura H, Kirschner AN, Longnecker R, Jardetzky TS. Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H\/glycoprotein L (gH\/gL) complex. Proc Natl Acad Sci U S A. 2010;107(52):22641\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"4523_CR50","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1073\/pnas.0810530106","volume":"106","author":"M Backovic","year":"2009","unstructured":"Backovic M, Longnecker R, Jardetzky TS. Structure of a trimeric variant of the Epstein-Barr virus glycoprotein B. Proc Natl Acad Sci U S A. 2009;106(8):2880\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"4523_CR51","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/nsmb.1782","volume":"17","author":"E Seiradake","year":"2010","unstructured":"Seiradake E, Harlos K, Sutton G, Aricescu AR, Jones EY. An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly. Nat Struct Mol Biol. 2010;17(4):398\u2013402.","journal-title":"Nat Struct Mol Biol"},{"issue":"7","key":"4523_CR52","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1172\/JCI136225","volume":"130","author":"JI Cohen","year":"2020","unstructured":"Cohen JI. Herpesvirus latency. J Clin Invest. 2020;130(7):3361\u20139.","journal-title":"J Clin Invest"},{"issue":"Pt 1","key":"4523_CR53","first-page":"151","volume":"390","author":"DA Thorley-Lawson","year":"2015","unstructured":"Thorley-Lawson DA. EBV persistence-introducing the virus. Curr Top Microbiol Immunol. 2015;390(Pt 1):151\u2013209.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"6","key":"4523_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002505","volume":"3","author":"N Mutalima","year":"2008","unstructured":"Mutalima N, Molyneux E, Jaffe H, Kamiza S, Borgstein E, Mkandawire N, et al. Associations between Burkitt lymphoma among children in Malawi and infection with HIV, EBV and malaria: results from a case-control study. PLoS ONE. 2008;3(6):e2505.","journal-title":"PLoS ONE"},{"issue":"2","key":"4523_CR55","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/(SICI)1099-1654(200003\/04)10:2<83::AID-RMV262>3.0.CO;2-T","volume":"10","author":"ER Leight","year":"2000","unstructured":"Leight ER, Sugden B. EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus. Rev Med Virol. 2000;10(2):83\u2013100.","journal-title":"Rev Med Virol"},{"issue":"17","key":"4523_CR56","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00949-22","volume":"96","author":"Y Mei","year":"2022","unstructured":"Mei Y, Messick TE, Dheekollu J, Kim HJ, Molugu S, Munoz LJC, et al. Cryo-EM structure and functional studies of EBNA1 binding to the family of repeats and dyad symmetry elements of Epstein-Barr virus oriP. J Virol. 2022;96(17):e0094922.","journal-title":"J Virol"},{"issue":"Pt A","key":"4523_CR57","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.biochi.2023.07.010","volume":"214","author":"VT Dinh","year":"2023","unstructured":"Dinh VT, Loaec N, Quillevere A, Le Senechal R, Keruzore M, Martins RP, et al. The hide-and-seek game of the oncogenic Epstein-Barr virus-encoded EBNA1 protein with the immune system: an RNA G-quadruplex tale. Biochimie. 2023;214(Pt A):57\u201368.","journal-title":"Biochimie"},{"issue":"7957","key":"4523_CR58","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41586-023-05923-x","volume":"616","author":"JSZ Li","year":"2023","unstructured":"Li JSZ, Abbasi A, Kim DH, Lippman SM, Alexandrov LB, Cleveland DW. Chromosomal fragile site breakage by EBV-encoded EBNA1 at clustered repeats. Nature. 2023;616(7957):504\u20139.","journal-title":"Nature"},{"issue":"3","key":"4523_CR59","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nsmb1067","volume":"13","author":"Y Sheng","year":"2006","unstructured":"Sheng Y, Saridakis V, Sarkari F, Duan S, Wu T, Arrowsmith CH, et al. Molecular recognition of p53 and MDM2 by USP7\/HAUSP. Nat Struct Mol Biol. 2006;13(3):285\u201391.","journal-title":"Nat Struct Mol Biol"},{"key":"4523_CR60","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01771-01719","author":"Q Peng","year":"2020","unstructured":"Peng Q, Wang L, Qin Z, Wang J, Zheng X, Wei L, et al. Phase separation of epstein-barr virus EBNA2 and its coactivator EBNALP controls gene expression. J Virol. 2020. https:\/\/doi.org\/10.1128\/jvi.01771-01719.","journal-title":"J Virol"},{"key":"4523_CR61","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.virol.2021.02.004","volume":"557","author":"Y Yanagi","year":"2021","unstructured":"Yanagi Y, Okuno Y, Narita Y, Masud H, Watanabe T, Sato Y, et al. RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells. Virology. 2021;557:44\u201354.","journal-title":"Virology"},{"issue":"18","key":"4523_CR62","doi-asserted-by":"publisher","first-page":"10657","DOI":"10.1093\/nar\/gkab787","volume":"49","author":"E Manet","year":"2021","unstructured":"Manet E, Polveche H, Mure F, Mrozek-Gorska P, Roisne-Hamelin F, Hammerschmidt W, et al. Modulation of alternative splicing during early infection of human primary B lymphocytes with Epstein-Barr virus (EBV): a novel function for the viral EBNA-LP protein. Nucleic Acids Res. 2021;49(18):10657\u201376.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"4523_CR63","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41588-018-0102-3","volume":"50","author":"JB Harley","year":"2018","unstructured":"Harley JB, Chen X, Pujato M, Miller D, Maddox A, Forney C, et al. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat Genet. 2018;50(5):699\u2013707.","journal-title":"Nat Genet"},{"issue":"12","key":"4523_CR64","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1099\/0022-1317-82-12-3067","volume":"82","author":"EM McCann","year":"2001","unstructured":"McCann EM, Kelly GL, Rickinson AB, Bell AI. Genetic analysis of the Epstein-Barr virus-coded leader protein EBNA-LP as a co-activator of EBNA2 function. J Gen Virol. 2001;82(12):3067\u201379.","journal-title":"J Gen Virol"},{"issue":"9","key":"4523_CR65","doi-asserted-by":"publisher","first-page":"6611","DOI":"10.1128\/jvi.71.9.6611-6618.1997","volume":"71","author":"S Harada","year":"1997","unstructured":"Harada S, Kieff E. Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation. J Virol. 1997;71(9):6611\u20138.","journal-title":"J Virol"},{"issue":"14","key":"4523_CR66","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1002\/j.1460-2075.1994.tb06634.x","volume":"13","author":"AJ Sinclair","year":"1994","unstructured":"Sinclair AJ, Palmero I, Peters G, Farrell PJ. EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J. 1994;13(14):3321\u20138.","journal-title":"EMBO J"},{"issue":"51","key":"4523_CR67","doi-asserted-by":"publisher","first-page":"19278","DOI":"10.1073\/pnas.0609320103","volume":"103","author":"D Portal","year":"2006","unstructured":"Portal D, Rosendorff A, Kieff E. Epstein\u2013Barr nuclear antigen leader protein coactivates transcription through interaction with histone deacetylase 4. Proc Natl Acad Sci USA. 2006;103(51):19278\u201383.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4523_CR68","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02155-02117","author":"C Wang","year":"2018","unstructured":"Wang C, Zhou H, Xue Y, Liang J, Narita Y, Gerdt C, et al. Epstein-barr virus nuclear antigen leader protein coactivates EP300. J Virol. 2018. https:\/\/doi.org\/10.1128\/jvi.02155-02117.","journal-title":"J Virol"},{"issue":"6","key":"4523_CR69","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1093\/nar\/gky1323","volume":"47","author":"K Paschos","year":"2019","unstructured":"Paschos K, Bazot Q, Lees J, Farrell PJ, Allday MJ. Requirement for PRC1 subunit BMI1 in host gene activation by Epstein-Barr virus protein EBNA3C. Nucleic Acids Res. 2019;47(6):2807\u201321.","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"4523_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004415","volume":"10","author":"ML Tursiella","year":"2014","unstructured":"Tursiella ML, Bowman ER, Wanzeck KC, Throm RE, Liao J, Zhu J, et al. Epstein-Barr virus nuclear antigen 3A promotes cellular proliferation by repression of the cyclin-dependent kinase inhibitor p21WAF1\/CIP1. PLoS Pathog. 2014;10(10):e1004415.","journal-title":"PLoS Pathog"},{"issue":"4","key":"4523_CR71","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1128\/JVI.78.4.1981-1991.2004","volume":"78","author":"JS Knight","year":"2004","unstructured":"Knight JS, Robertson ES. Epstein-Barr virus nuclear antigen 3C regulates cyclin A\/p27 complexes and enhances cyclin A-dependent kinase activity. J Virol. 2004;78(4):1981\u201391.","journal-title":"J Virol"},{"key":"4523_CR72","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02168-02119","author":"JC Romero-Masters","year":"2020","unstructured":"Romero-Masters JC, Ohashi M, Djavadian R, Eichelberg MR, Hayes M, Zumwalde NA, et al. An EBNA3A-mutated epstein-barr virus retains the capacity for lymphomagenesis in a cord blood-humanized mouse model. J Virol. 2020. https:\/\/doi.org\/10.1128\/jvi.02168-02119.","journal-title":"J Virol"},{"issue":"1","key":"4523_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens7010031","volume":"7","author":"CT Styles","year":"2018","unstructured":"Styles CT, Paschos K, White RE, Farrell PJ. The cooperative functions of the EBNA3 proteins are central to EBV persistence and latency. Pathogens. 2018;7(1):31.","journal-title":"Pathogens"},{"issue":"3","key":"4523_CR74","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.4049\/jimmunol.160.3.1116","volume":"160","author":"E Hatzivassiliou","year":"1998","unstructured":"Hatzivassiliou E, Miller WE, Raab-Traub N, Kieff E, Mosialos G. A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-\u03baB, and stress-activated protein kinase. J Immunol. 1998;160(3):1116\u201321.","journal-title":"J Immunol"},{"issue":"26","key":"4523_CR75","doi-asserted-by":"publisher","first-page":"15595","DOI":"10.1073\/pnas.2136756100","volume":"100","author":"M Luftig","year":"2003","unstructured":"Luftig M, Prinarakis E, Yasui T, Tsichritzis T, Cahir-McFarland E, Inoue J-I, et al. Epstein-Barr virus latent membrane protein 1 activation of NF-\u03baB through IRAK1 and TRAF6. Proc Natl Acad Sci U S A. 2003;100(26):15595\u2013600.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"4523_CR76","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1128\/JVI.01703-10","volume":"85","author":"C-P Kung","year":"2011","unstructured":"Kung C-P, Meckes JDG, Raab-Traub N. Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKC\u03b4. J Virol. 2011;85(9):4399\u2013408.","journal-title":"J Virol"},{"issue":"18","key":"4523_CR77","doi-asserted-by":"publisher","first-page":"9680","DOI":"10.1128\/JVI.01001-07","volume":"81","author":"BA Mainou","year":"2007","unstructured":"Mainou BA, Everly DN Jr., Raab-Traub N. Unique signaling properties of CTAR1 in LMP1-mediated transformation. J Virol. 2007;81(18):9680\u201392.","journal-title":"J Virol"},{"issue":"13","key":"4523_CR78","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/sj.onc.1201694","volume":"16","author":"AG Eliopoulos","year":"1998","unstructured":"Eliopoulos AG, Young LS. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene. 1998;16(13):1731\u201342.","journal-title":"Oncogene"},{"issue":"21","key":"4523_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215451","volume":"13","author":"L Wang","year":"2021","unstructured":"Wang L, Ning S. New look of EBV LMP1 signaling landscape. Cancers (Basel). 2021;13(21):5451.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4523_CR80","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/iub.1240","volume":"66","author":"A Varadaraj","year":"2014","unstructured":"Varadaraj A, Mattoscio D, Chiocca S. SUMO ubc9 enzyme as a viral target. IUBMB Life. 2014;66(1):27\u201333.","journal-title":"IUBMB Life"},{"issue":"4","key":"4523_CR81","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1128\/JVI.79.4.2375-2382.2005","volume":"79","author":"JA Morrison","year":"2005","unstructured":"Morrison JA, Raab-Traub N. Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of beta-catenin signaling. J Virol. 2005;79(4):2375\u201382.","journal-title":"J Virol"},{"key":"4523_CR82","unstructured":"Brandon J. The Src family tyrosine kinase, Lyn, negatively regulates Akt activation in LMP2A-expressing B lymphocytes (Doctoral dissertation). 2008."},{"issue":"9","key":"4523_CR83","doi-asserted-by":"publisher","first-page":"5529","DOI":"10.1128\/JVI.77.9.5529-5534.2003","volume":"77","author":"A Ikeda","year":"2003","unstructured":"Ikeda A, Caldwell RG, Longnecker R, Ikeda M. Itchy, a Nedd4 ubiquitin ligase, downregulates latent membrane protein 2A activity in B-cell signaling. J Virol. 2003;77(9):5529\u201334.","journal-title":"J Virol"},{"issue":"3","key":"4523_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031709","volume":"23","author":"HY Pan","year":"2022","unstructured":"Pan HY, Valapala M. Regulation of autophagy by the glycogen synthase kinase-3 (GSK-3) signaling pathway. Int J Mol Sci. 2022;23(3):1709.","journal-title":"Int J Mol Sci"},{"key":"4523_CR85","volume":"1","author":"O D\u2019Cruz","year":"2012","unstructured":"D\u2019Cruz O, Uckun F. Targeting spleen tyrosine kinase (SYK) for treatment of human disease. J Pharm Drug Deliv Res. 2012;1:2.","journal-title":"J Pharm Drug Deliv Res"},{"key":"4523_CR86","volume-title":"Epstein\u2013barr virus evasion of intrinsic and innate immune pathways during the viral lytic cycle","author":"SPT Yiu","year":"2023","unstructured":"Yiu SPT. Epstein\u2013barr virus evasion of intrinsic and innate immune pathways during the viral lytic cycle. Harvard: Harvard University; 2023."},{"key":"4523_CR87","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.coviro.2021.11.013","volume":"52","author":"R Guo","year":"2022","unstructured":"Guo R, Gewurz BE. Epigenetic control of the Epstein-Barr lifecycle. Curr Opin Virol. 2022;52:78\u201388.","journal-title":"Curr Opin Virol"},{"issue":"11","key":"4523_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002376","volume":"7","author":"K Tsai","year":"2011","unstructured":"Tsai K, Thikmyanova N, Wojcechowskyj JA, Delecluse HJ, Lieberman PM. EBV tegument protein BNRF1 disrupts DAXX-ATRX to activate viral early gene transcription. PLoS Pathog. 2011;7(11):e1002376.","journal-title":"PLoS Pathog"},{"issue":"1","key":"4523_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009208","volume":"17","author":"RJ Lamontagne","year":"2021","unstructured":"Lamontagne RJ, Soldan SS, Su C, Wiedmer A, Won KJ, Lu F, et al. A multi-omics approach to Epstein-Barr virus immortalization of B-cells reveals EBNA1 chromatin pioneering activities targeting nucleotide metabolism. PLoS Pathog. 2021;17(1):e1009208.","journal-title":"PLoS Pathog"},{"key":"4523_CR90","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01390-01320","author":"L Wang","year":"2020","unstructured":"Wang L, Laing J, Yan B, Zhou H, Ke L, Wang C, et al. Epstein-barr virus episome physically interacts with active regions of the host genome in lymphoblastoid cells. J Virol. 2020. https:\/\/doi.org\/10.1128\/jvi.01390-01320.","journal-title":"J Virol"},{"issue":"1","key":"4523_CR91","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/carcin\/bgaa123","volume":"42","author":"K Kase","year":"2021","unstructured":"Kase K, Saito M, Nakajima S, Takayanagi D, Saito K, Yamada L, et al. ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation. Carcinogenesis. 2021;42(1):21\u201330.","journal-title":"Carcinogenesis"},{"issue":"8","key":"4523_CR92","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.7150\/jca.42498","volume":"11","author":"W Li","year":"2020","unstructured":"Li W, He C, Wu J, Yang D, Yi W. Epstein barr virus encodes miRNAs to assist host immune escape. J Cancer. 2020;11(8):2091\u2013100.","journal-title":"J Cancer"},{"issue":"3","key":"4523_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24031964","volume":"24","author":"G Roy","year":"2023","unstructured":"Roy G, Yang T, Liu S, Luo YL, Liu Y, Zhong Q. Epigenetic regulation of MAP3K8 in EBV-associated gastric carcinoma. Int J Mol Sci. 2023;24(3):1964.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4523_CR94","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00655-22","volume":"13","author":"RH Edwards","year":"2022","unstructured":"Edwards RH, Raab-Traub N. Major role for cellular microRNAs, long noncoding RNAs (lncRNAs), and the Epstein-Barr virus-encoded BART lncRNA during tumor growth in vivo. MBio. 2022;13(3):e0065522.","journal-title":"MBio"},{"issue":"15 suppl","key":"4523_CR95","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.e15509","volume":"37","author":"R Sundar","year":"2019","unstructured":"Sundar R, Qamra A, Tan ALK, Zhang S, Ng CCY, Teh BT, et al. Epigenetic alternate promoter utilization and association with PD-L1 expression in Epstein-Barr virus positive gastric cancer. J Clin Oncol. 2019;37(15 suppl):e15509.","journal-title":"J Clin Oncol"},{"issue":"22","key":"4523_CR96","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01209-20","volume":"94","author":"Y Pei","year":"2020","unstructured":"Pei Y, Wong JH, Jha HC, Tian T, Wei Z, Robertson ES. Epstein-Barr virus facilitates expression of KLF14 by regulating the cooperative binding of the E2F-Rb-HDAC complex in latent infection. J Virol. 2020;94(22):10.1128\/jvi.01209-01220.","journal-title":"J Virol"},{"key":"4523_CR97","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2015.13","volume":"17","author":"Y Tao","year":"2015","unstructured":"Tao Y, Shi Y, Jia J, Jiang Y, Yang L, Cao Y. Novel roles and therapeutic targets of Epstein-Barr virus-encoded latent membrane protein 1-induced oncogenesis in nasopharyngeal carcinoma. Expert Rev Mol Med. 2015;17:e15.","journal-title":"Expert Rev Mol Med"},{"issue":"6","key":"4523_CR98","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1007\/s10565-023-09830-9","volume":"39","author":"CK Looi","year":"2023","unstructured":"Looi CK, Foong LC, Chung FF, Khoo AS, Loo EM, Leong CO, et al. Targeting the crosstalk of epigenetic modifications and immune evasion in nasopharyngeal cancer. Cell Biol Toxicol. 2023;39(6):2501\u201326.","journal-title":"Cell Biol Toxicol"},{"issue":"20","key":"4523_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205189","volume":"13","author":"M Bauer","year":"2021","unstructured":"Bauer M, Jasinski-Bergner S, Mandelboim O, Wickenhauser C, Seliger B. Epstein-Barr virus-associated malignancies and immune escape: the role of the tumor microenvironment and tumor cell evasion strategies. Cancers (Basel). 2021;13(20):5189.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"4523_CR100","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720\u201348.","journal-title":"Leukemia"},{"issue":"4","key":"4523_CR101","doi-asserted-by":"publisher","first-page":"T378","DOI":"10.1016\/j.ad.2025.02.009","volume":"116","author":"S Garcia-Gonzalez","year":"2025","unstructured":"Garcia-Gonzalez S, Prieto-Torres L, Garcia-Garcia M. [Translated article] An Update on EBV-related Cutaneous Lymphoproliferative Disorders: a Systematic Review. Actas Dermosifiliogr. 2025;116(4):T378\u201393.","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"4523_CR102","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.beha.2013.04.002","volume":"26","author":"N Asano","year":"2013","unstructured":"Asano N, Kato S, Nakamura S. Epstein-Barr virus-associated natural killer\/T-cell lymphomas. Best Pract Res Clin Haematol. 2013;26(1):15\u201321.","journal-title":"Best Pract Res Clin Haematol"},{"key":"4523_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2018.00292","volume":"6","author":"F Ishida","year":"2018","unstructured":"Ishida F. Aggressive NK-cell leukemia. Front Pediatr. 2018;6:292.","journal-title":"Front Pediatr"},{"issue":"1","key":"4523_CR104","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13052-024-01685-y","volume":"50","author":"D Dilmurat","year":"2024","unstructured":"Dilmurat D, Wang X, Gao L, Tian J, Ai J, Zhang L, et al. Clinical epidemiology of Epstein-Barr virus-associated lymphoproliferative disorders (EBV-LPDs) in hospitalized children: a six-year multi-institutional study in China. Ital J Pediatr. 2024;50(1):125.","journal-title":"Ital J Pediatr"},{"issue":"2","key":"4523_CR105","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1182\/bloodadvances.2021005291","volume":"6","author":"BJ Davila Saldana","year":"2022","unstructured":"Davila Saldana BJ, John T, Bonifant C, Buchbinder D, Chandra S, Chandrakasan S, et al. High risk of relapsed disease in patients with NK\/T-cell chronic active Epstein-Barr virus disease outside of Asia. Blood Adv. 2022;6(2):452\u20139.","journal-title":"Blood Adv"},{"issue":"12","key":"4523_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123542","volume":"12","author":"J Domagala","year":"2020","unstructured":"Domagala J, Lachota M, Klopotowska M, Graczyk-Jarzynka A, Domagala A, Zhylko A, et al. The tumor microenvironment-a metabolic obstacle to NK cells\u2019 activity. Cancers (Basel). 2020;12(12):3542.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"4523_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06999-7","volume":"15","author":"W Song","year":"2024","unstructured":"Song W, Gao Y, Wu J, Li H, Shi Z, Gong C, et al. LMP1 enhances aerobic glycolysis in natural killer\/T cell lymphoma. Cell Death Dis. 2024;15(8):604.","journal-title":"Cell Death Dis"},{"key":"4523_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103614","volume":"72","author":"J Xiong","year":"2021","unstructured":"Xiong J, Wang N, Zhong HJ, Cui BW, Cheng S, Sun R, et al. SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential. EBioMedicine. 2021;72:103614.","journal-title":"EBioMedicine"},{"key":"4523_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111516","author":"A Kumar","year":"2022","unstructured":"Kumar A, Yarosz EL, Andren A, Zhang L, Lyssiotis CA, Chang C-H. NKT cells adopt a glutamine-addicted phenotype to regulate their homeostasis and function. Cell Rep. 2022. https:\/\/doi.org\/10.1016\/j.celrep.2022.111516.","journal-title":"Cell Rep"},{"key":"4523_CR110","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.87536","volume":"12","author":"J Koh","year":"2023","unstructured":"Koh J, Woo YD, Yoo HJ, Choi J-P, Kim SH, Chang Y-S, et al. De novo fatty-acid synthesis protects invariant NKT cells from cell death, thereby promoting their homeostasis and pathogenic roles in airway hyperresponsiveness. Elife. 2023;12:RP87536.","journal-title":"Elife"},{"issue":"5","key":"4523_CR111","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41590-020-0666-9","volume":"21","author":"T Baumann","year":"2020","unstructured":"Baumann T, Dunkel A, Schmid C, Schmitt S, Hiltensperger M, Lohr K, et al. Regulatory myeloid cells paralyze T cells through cell\u2013cell transfer of the metabolite methylglyoxal. Nat Immunol. 2020;21(5):555\u201366.","journal-title":"Nat Immunol"},{"issue":"1","key":"4523_CR112","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-023-01436-6","volume":"15","author":"J Chen","year":"2023","unstructured":"Chen J, Zuo Z, Gao Y, Yao X, Guan P, Wang Y, et al. Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK\/T-cell lymphoma to chidamide. Clin Epigenetics. 2023;15(1):19.","journal-title":"Clin Epigenetics"},{"issue":"19","key":"4523_CR113","doi-asserted-by":"publisher","first-page":"17764","DOI":"10.18632\/oncotarget.3776","volume":"6","author":"S Lee","year":"2015","unstructured":"Lee S, Park HY, Kang SY, Kim SJ, Hwang J, Lee S, et al. Genetic alterations of JAK\/STAT cascade and histone modification in extranodal NK\/T-cell lymphoma nasal type. Oncotarget. 2015;6(19):17764\u201376.","journal-title":"Oncotarget"},{"issue":"2","key":"4523_CR114","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/cr.2017.146","volume":"28","author":"L Huang","year":"2018","unstructured":"Huang L, Liu D, Wang N, Ling S, Tang Y, Wu J, et al. Integrated genomic analysis identifies deregulated JAK\/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Res. 2018;28(2):172\u201386.","journal-title":"Cell Res"},{"issue":"4","key":"4523_CR115","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1751-553X.2009.01204.x","volume":"32","author":"M Tsutsui","year":"2010","unstructured":"Tsutsui M, Yasuda H, Suto H, Imai H, Isobe Y, Sasaki M, et al. Frequent STAT3 activation is associated with Mcl-1 expression in nasal NK-cell lymphoma. Int J Lab Hematol. 2010;32(4):419\u201326.","journal-title":"Int J Lab Hematol"},{"issue":"6","key":"4523_CR116","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s12026-024-09531-3","volume":"72","author":"W Chen","year":"2024","unstructured":"Chen W, Xie Y, Li F, Wen P, Wang L. EBV + B cell-derived exosomes promote EBV-associated T\/NK-cell lymphoproliferative disease immune evasion by STAT3\/IL-10\/PD-L1 pathway. Immunol Res. 2024;72(6):1327\u201336.","journal-title":"Immunol Res"},{"issue":"3","key":"4523_CR117","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28667","volume":"95","author":"Q Wang","year":"2023","unstructured":"Wang Q, He H, Ji X, Liu Y, Li H, Wang Y. BART-D2 subtype of EBV encoded BART miRNA cluster 1 region is strongly associated with endemic nasopharyngeal carcinoma. J Med Virol. 2023;95(3):e28667.","journal-title":"J Med Virol"},{"issue":"8","key":"4523_CR118","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.2174\/1871520621666210908103306","volume":"22","author":"L Xu","year":"2022","unstructured":"Xu L, Qin Y, Liu M, Jiao J, Tu D, Zhang M, et al. The acetyltransferase KAT5 inhibitor NU 9056 promotes apoptosis and inhibits JAK2\/STAT3 pathway in extranodal NK\/T cell lymphoma. Anticancer Agents Med Chem. 2022;22(8):1530\u201340.","journal-title":"Anticancer Agents Med Chem"},{"key":"4523_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217058","volume":"597","author":"S Wu","year":"2024","unstructured":"Wu S, Wang H, Yang Q, Liu Z, Du J, Wang L, et al. METTL3 regulates M6A methylation-modified EBV-pri-miR-BART3-3p to promote NK\/T cell lymphoma growth. Cancer Lett. 2024;597:217058.","journal-title":"Cancer Lett"},{"key":"4523_CR120","volume-title":"Open forum infectious diseases","author":"J Jin","year":"2023","unstructured":"Jin J, Sun T, Zhang M, Cheng J, Gu J, Huang L, et al. EBV-encoded MicroRNA-BART17\u20133p targets DDX3X and promotes EBV infection in EBV-associated t\/natural killer-cell lymphoproliferative diseases. In: Jin J, Sun T, Zhang M, Cheng J, editors. Open forum infectious diseases. Oxford: Oxford University Press US; 2023."},{"issue":"6","key":"4523_CR121","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007796","volume":"15","author":"F Lang","year":"2019","unstructured":"Lang F, Singh RK, Pei Y, Zhang S, Sun K, Robertson ES. EBV epitranscriptome reprogramming by METTL14 is critical for viral-associated tumorigenesis. PLoS Pathog. 2019;15(6):e1007796.","journal-title":"PLoS Pathog"},{"key":"4523_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2022.105320","volume":"157","author":"Z Yan","year":"2022","unstructured":"Yan Z, Yao Z, Wang H, Yao S, Wang X, Gao Y, et al. Plasma EBV-DNA and peripheral blood mononuclear cell EBV-DNA have disparate clinical relevance in patients with extranodal NK\/T-cell lymphoma. J Clin Virol. 2022;157:105320.","journal-title":"J Clin Virol"},{"issue":"23","key":"4523_CR123","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.1182\/blood-2011-05-354142","volume":"118","author":"R Suzuki","year":"2011","unstructured":"Suzuki R, Yamaguchi M, Izutsu K, Yamamoto G, Takada K, Harabuchi Y, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK\/T-cell lymphoma, nasal type. Blood. 2011;118(23):6018\u201322.","journal-title":"Blood"},{"issue":"3","key":"4523_CR124","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/hon.2998","volume":"40","author":"M Zheng","year":"2022","unstructured":"Zheng M, Bao Y, Wang J, Ma Y, Yang Y, Zhang P, et al. The superiority of Epstein-Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV-positive NK-cell lymphoproliferative diseases. Hematol Oncol. 2022;40(3):381\u20139.","journal-title":"Hematol Oncol"},{"issue":"8","key":"4523_CR125","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.3324\/haematol.2021.280003","volume":"107","author":"CMM Wai","year":"2022","unstructured":"Wai CMM, Chen S, Phyu T, Fan S, Leong SM, Zheng W, et al. Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T\/NK-cell lymphoma from ENKTL and PTCL-NOS. Haematologica. 2022;107(8):1864\u201379.","journal-title":"Haematologica"},{"issue":"19","key":"4523_CR126","first-page":"4775","volume":"4","author":"N Sejic","year":"2020","unstructured":"Sejic N, George LC, Tierney RJ, Chang C, Kondrashova O, MacKinnon RN, et al. BCL-XL inhibition by BH3-mimetic drugs induces apoptosis in models of Epstein-Barr virus-associated T\/NK-cell lymphoma. Blood Adv. 2020;4(19):4775\u201387.","journal-title":"Blood Adv"},{"key":"4523_CR127","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186461","volume":"142","author":"S Kinoshita","year":"2023","unstructured":"Kinoshita S, Ishii M, Furukawa Y, Sato S, Ando J, Nakauchi H, et al. iPSC-derived dual antigen receptor T cells targeting GD2 and LMP2 antigens for extranodal NK\/T-cell lymphoma, nasal type. Blood. 2023;142:2079.","journal-title":"Blood"},{"issue":"7","key":"4523_CR128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133973","volume":"10","author":"CG Song","year":"2015","unstructured":"Song CG, Huang JJ, Li YJ, Xia Y, Wang Y, Bi XW, et al. Epstein-barr virus-positive diffuse large B-cell lymphoma in the elderly: a matched case-control analysis. PLoS ONE. 2015;10(7):e0133973.","journal-title":"PLoS ONE"},{"issue":"8","key":"4523_CR129","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081785","volume":"13","author":"J Hwang","year":"2021","unstructured":"Hwang J, Suh CH, Won Kim K, Kim HS, Armand P, Huang RY, et al. The incidence of Epstein-Barr virus-positive diffuse large B-cell lymphoma: a systematic review and meta-analysis. Cancers (Basel). 2021;13(8):1785.","journal-title":"Cancers (Basel)"},{"issue":"20","key":"4523_CR130","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"issue":"12","key":"4523_CR131","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1111\/j.1349-7006.2000.tb00909.x","volume":"91","author":"T Kuze","year":"2000","unstructured":"Kuze T, Nakamura N, Hashimoto Y, Sasaki Y, Abe M. The characteristics of Epstein\u2010barr virus (EBV)\u2010positive diffuse large B\u2010cell lymphoma: comparison between EBV+ and EBV\u2010cases in Japanese population. Jpn J Cancer Res. 2000;91(12):1233\u201340.","journal-title":"Jpn J Cancer Res"},{"issue":"1","key":"4523_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2014.82","volume":"47","author":"CY Ok","year":"2015","unstructured":"Ok CY, Li L, Young KH. EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management. Exp Mol Med. 2015;47(1):e132.","journal-title":"Exp Mol Med"},{"issue":"1","key":"4523_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-017-0262-z","volume":"36","author":"LY Hu","year":"2017","unstructured":"Hu LY, Xu XL, Rao HL, Chen J, Lai RC, Huang HQ, et al. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study. Chin J Cancer. 2017;36(1):94.","journal-title":"Chin J Cancer"},{"issue":"1072","key":"4523_CR134","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20160879","volume":"90","author":"K Tokuyama","year":"2017","unstructured":"Tokuyama K, Okada F, Sato H, Matsumoto S, Matsumoto A, Haruno A, et al. Computed tomography findings in Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of the elderly: comparison with EBV-negative DLBCL. Br J Radiol. 2017;90(1072):20160879.","journal-title":"Br J Radiol"},{"key":"4523_CR135","doi-asserted-by":"crossref","unstructured":"Lu TX, Liang JH, Miao Y, Fan L, Wang L, Qu XY, Cao L, Gong QX, Wang Z, Zhang ZH et al: Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. Sci Rep. 2015;5:12168.","DOI":"10.1038\/srep12168"},{"issue":"5","key":"4523_CR136","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/ajt.12196","volume":"13","author":"J Morscio","year":"2013","unstructured":"Morscio J, Dierickx D, Ferreiro J, Herreman A, Van Loo P, Bittoun E, et al. Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant. 2013;13(5):1305\u201316.","journal-title":"Am J Transplant"},{"issue":"1","key":"4523_CR137","doi-asserted-by":"publisher","DOI":"10.3390\/biom10010128","volume":"10","author":"S Banjara","year":"2020","unstructured":"Banjara S, Suraweera CD, Hinds MG, Kvansakul M. The Bcl-2 family: ancient origins, conserved structures, and divergent mechanisms. Biomolecules. 2020;10(1):128.","journal-title":"Biomolecules"},{"issue":"1","key":"4523_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14502-x","volume":"11","author":"S Voigt","year":"2020","unstructured":"Voigt S, Sterz KR, Giehler F, Mohr AW, Wilson JB, Moosmann A, et al. A central role of IKK2 and TPL2 in JNK activation and viral B-cell transformation. Nat Commun. 2020;11(1):685.","journal-title":"Nat Commun"},{"issue":"8","key":"4523_CR139","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1128\/JVI.06966-11","volume":"86","author":"ZL Pratt","year":"2012","unstructured":"Pratt ZL, Zhang J, Sugden B. The latent membrane protein 1 (LMP1) oncogene of Epstein-Barr virus can simultaneously induce and inhibit apoptosis in B cells. J Virol. 2012;86(8):4380\u201393.","journal-title":"J Virol"},{"issue":"3","key":"4523_CR140","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1182\/blood-2007-10-117655","volume":"111","author":"J Rastelli","year":"2008","unstructured":"Rastelli J, H\u00f6mig-H\u00f6lzel C, Seagal J, M\u00fcller W, Hermann AC, Rajewsky K, et al. LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1. Blood. 2008;111(3):1448\u201355.","journal-title":"Blood"},{"key":"4523_CR141","first-page":"119","volume":"391","author":"A Kieser","year":"2015","unstructured":"Kieser A, Sterz KR. The latent membrane protein 1 (LMP1). Curr Top Microbiol Immunol. 2015;391:119\u201349.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"8","key":"4523_CR142","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1128\/JVI.78.8.4108-4119.2004","volume":"78","author":"ED Cahir-McFarland","year":"2004","unstructured":"Cahir-McFarland ED, Carter K, Rosenwald A, Giltnane JM, Henrickson SE, Staudt LM, et al. Role of NF-\u03baB in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol. 2004;78(8):4108\u201319.","journal-title":"J Virol"},{"issue":"11","key":"4523_CR143","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1128\/JVI.00125-08","volume":"82","author":"C-P Kung","year":"2008","unstructured":"Kung C-P, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor through effects on Bcl-3 and STAT3. J Virol. 2008;82(11):5486\u201393.","journal-title":"J Virol"},{"issue":"1","key":"4523_CR144","first-page":"219","volume":"32","author":"J-J Gao","year":"2024","unstructured":"Gao J-J, Zhu X-P, Wang M-Q, Lin X-Z, Zhuang Y-L, Lin H-J. Mechanism about LMP1 of EB virus promoting plasma blast differentiation of DLBCL cell via mTORC1. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024;32(1):219\u201324.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"4523_CR145","first-page":"388","volume-title":"Seminars in cancer biology","author":"J Middeldorp","year":"2008","unstructured":"Middeldorp J, Pegtel D. Multiple roles of LMP1 in Epstein-Barr virus induced immune escape. In: Middeldorp J, Pegtel D, editors. Seminars in cancer biology. Amsterdam: Elsevier; 2008. p. 388\u201396."},{"issue":"1","key":"4523_CR146","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1006\/viro.2001.1187","volume":"291","author":"M Merchant","year":"2001","unstructured":"Merchant M, Longnecker R. LMP2A survival and developmental signals are transmitted through Btk-dependent and Btk-independent pathways. Virology. 2001;291(1):46\u201354.","journal-title":"Virology"},{"issue":"34","key":"4523_CR147","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1038\/onc.2014.380","volume":"34","author":"X Zhou","year":"2015","unstructured":"Zhou X, Matskova L, Rathje LS, Xiao X, Gish G, Werner M, et al. SYK interaction with ITGbeta4 suppressed by Epstein-Barr virus LMP2A modulates migration and invasion of nasopharyngeal carcinoma cells. Oncogene. 2015;34(34):4491\u20139.","journal-title":"Oncogene"},{"issue":"42","key":"4523_CR148","doi-asserted-by":"publisher","first-page":"26318","DOI":"10.1073\/pnas.2007946117","volume":"117","author":"K Fish","year":"2020","unstructured":"Fish K, Comoglio F, Shaffer IIIAL, Ji Y, Pan K-T, Scheich S, et al. Rewiring of B cell receptor signaling by Epstein\u2013Barr virus LMP2A. Proc Natl Acad Sci. 2020;117(42):26318\u201327.","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"4523_CR149","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3858\/emm.2008.40.5.565","volume":"40","author":"NH Cho","year":"2008","unstructured":"Cho NH, Choi YK, Choi JK. Multi-transmembrane protein K15 of Kaposi\u2019s sarcoma-associated herpesvirus targets Lyn kinase in the membrane raft and induces NFAT\/AP1 activities. Exp Mol Med. 2008;40(5):565\u201373.","journal-title":"Exp Mol Med"},{"issue":"30","key":"4523_CR150","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2200512119","volume":"119","author":"S Beer","year":"2022","unstructured":"Beer S, Wange LE, Zhang X, Kuklik-Roos C, Enard W, Hammerschmidt W, et al. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells. Proc Natl Acad Sci U S A. 2022;119(30):e2200512119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"4523_CR151","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/his.14585","volume":"80","author":"H Liu","year":"2022","unstructured":"Liu H, Xu-Monette ZY, Tang G, Wang W, Kim Y, Yuan J, et al. EBV(+) high-grade B cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements: a multi-institutional study. Histopathology. 2022;80(3):575\u201388.","journal-title":"Histopathology"},{"issue":"2","key":"4523_CR152","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.biocel.2011.11.007","volume":"44","author":"Z Li","year":"2012","unstructured":"Li Z, Chen X, Li L, Liu S, Yang L, Ma X, et al. EBV encoded miR-BHRF1-1 potentiates viral lytic replication by downregulating host p53 in nasopharyngeal carcinoma. Int J Biochem Cell Biol. 2012;44(2):275\u20139.","journal-title":"Int J Biochem Cell Biol"},{"issue":"25","key":"4523_CR153","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1182\/blood.2019000889","volume":"134","author":"AS Cristino","year":"2019","unstructured":"Cristino AS, Nourse J, West RA, Sabdia MB, Law SC, Gunawardana J, et al. EBV microRNA-BHRF1-2-5p targets the 3\u2019UTR of immune checkpoint ligands PD-L1 and PD-L2. Blood. 2019;134(25):2261\u201370.","journal-title":"Blood"},{"key":"4523_CR154","doi-asserted-by":"publisher","first-page":"10475","DOI":"10.2147\/OTT.S253758","volume":"13","author":"C Sun","year":"2020","unstructured":"Sun C, Li M, Feng Y, Sun F, Zhang L, Xu Y, et al. MDM2-P53 signaling pathway-mediated upregulation of CDC20 promotes progression of human diffuse large B-cell lymphoma. Onco Targets Ther. 2020;13:10475\u201387.","journal-title":"Onco Targets Ther"},{"issue":"19","key":"4523_CR155","first-page":"3760","volume":"5","author":"RAL de Groen","year":"2021","unstructured":"de Groen RAL, van Eijk R, Bohringer S, van Wezel T, Raghoo R, Ruano D, et al. Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype. Blood Adv. 2021;5(19):3760\u201375.","journal-title":"Blood Adv"},{"issue":"6","key":"4523_CR156","first-page":"554","volume":"22","author":"L Weiming","year":"2024","unstructured":"Weiming L, Ming G, Weili X, Xiaoli L, Chang Y, Zhang K, et al. Palmitic acid reduces the methylation of the FOXO1 promoter to suppress the development of diffuse large B-cell lymphoma via modulating the miR-429\/DNMT3A axis. Chin J Nat Med. 2024;22(6):554\u201367.","journal-title":"Chin J Nat Med"},{"issue":"10","key":"4523_CR157","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.humimm.2023.07.007","volume":"84","author":"S Zheng","year":"2023","unstructured":"Zheng S, Ma J, Li J, Pang X, Ma M, Ma Z, et al. Lower PTEN may be associated with CD8+ T cell exhaustion in diffuse large B-cell lymphoma. Hum Immunol. 2023;84(10):551\u201360.","journal-title":"Hum Immunol"},{"key":"4523_CR158","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1182\/blood-2021-146335","volume":"138","author":"AJ Olszewski","year":"2021","unstructured":"Olszewski AJ, Sharaf R, Marcus C, Kurt H, Albacker LA, Vergilio J-A, et al. CDKN2A deletions define an unfavorable subgroup within the MYD88\/CD79B (MCD) subtype of diffuse large B-cell lymphoma (DLBCL) and are mutually exclusive with TP53 mutations. Blood. 2021;138:2392.","journal-title":"Blood"},{"issue":"2","key":"4523_CR159","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ijc.33802","volume":"150","author":"Z Shen","year":"2022","unstructured":"Shen Z, Hu L, Yao M, He C, Liu Q, Wang F, et al. Disparity analysis and prognostic value of pretreatment whole blood Epstein-Barr virus DNA load and Epstein-Barr encoding region status in lymphomas: a retrospective multicenter study in Huaihai Lymphoma Working Group. Int J Cancer. 2022;150(2):327\u201334.","journal-title":"Int J Cancer"},{"issue":"2","key":"4523_CR160","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/cam4.2710","volume":"9","author":"ND Montgomery","year":"2020","unstructured":"Montgomery ND, Randall C, Painschab M, Seguin R, Kaimila B, Kasonkanji E, et al. High pretreatment plasma Epstein-Barr virus (EBV) DNA level is a poor prognostic marker in HIV-associated, EBV-negative diffuse large B-cell lymphoma in Malawi. Cancer Med. 2020;9(2):552\u201361.","journal-title":"Cancer Med"},{"key":"4523_CR161","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004114","author":"T Zhang","year":"2022","unstructured":"Zhang T, Liu H, Jiao L, Zhang Z, He J, Li L, et al. Genetic characteristics involving the PD-1\/PD-L1\/L2 and CD73\/A2aR axes and the immunosuppressive microenvironment in DLBCL. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-004114.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4523_CR162","doi-asserted-by":"publisher","DOI":"10.1007\/s44313-024-00042-6","volume":"59","author":"Y Li","year":"2024","unstructured":"Li Y, Wu Y, Cao S, Yu B, Zhang Q, Xia Z, et al. PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL: a retrospective analysis. Blood Res. 2024;59(1):36.","journal-title":"Blood Res"},{"issue":"1","key":"4523_CR163","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01281-9","volume":"15","author":"J Huang","year":"2022","unstructured":"Huang J, Pang WS, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W, et al. Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. J Hematol Oncol. 2022;15(1):57.","journal-title":"J Hematol Oncol"},{"key":"4523_CR164","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-030-32482-7_1","volume-title":"Hodgkin Lymphoma: A Comprehensive Overview","author":"H Hjalgrim","year":"2020","unstructured":"Hjalgrim H, Jarrett RF. Epidemiology of Hodgkin lymphoma. In: Hjalgrim H, Jarrett RF, editors. Hodgkin Lymphoma: A Comprehensive Overview. Cham: Springer International Publishing; 2020. p. 3\u201323."},{"issue":"1","key":"4523_CR165","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0799-1","volume":"12","author":"L Zhou","year":"2019","unstructured":"Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, et al. Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study. J Hematol Oncol. 2019;12(1):107.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"4523_CR166","doi-asserted-by":"publisher","DOI":"10.3390\/v9070164","volume":"9","author":"H Knecht","year":"2017","unstructured":"Knecht H, Mai S. LMP1 and dynamic progressive telomere dysfunction: a major culprit in EBV-associated Hodgkin\u2019s lymphoma. Viruses. 2017;9(7):164.","journal-title":"Viruses"},{"issue":"11","key":"4523_CR167","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1080\/10428194.2019.1607330","volume":"60","author":"SP Aravinth","year":"2019","unstructured":"Aravinth SP, Rajendran S, Li Y, Wu M, Yi Wong AH, Schwarz H. Epstein-Barr virus-encoded LMP1 induces ectopic CD137 expression on Hodgkin and Reed-Sternberg cells via the PI3K-AKT-mTOR pathway. Leuk Lymphoma. 2019;60(11):2697\u2013704.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"4523_CR168","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1182\/blood.V95.1.294","volume":"95","author":"SH Kim","year":"2000","unstructured":"Kim SH, Shin YK, Lee IS, Bae YM, Sohn HW, Suh YH, et al. Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin\u2019s and Reed-Sternberg phenotype. Blood. 2000;95(1):294\u2013300.","journal-title":"Blood"},{"issue":"2","key":"4523_CR169","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s12253-010-9335-x","volume":"17","author":"P Zhao","year":"2011","unstructured":"Zhao P, Lu Y, Liu L, Zhong M. Aberrant cytoplasmic expression of cyclin B1 protein and its correlation with EBV-LMP1, P53 and P16(INK4A) in classical Hodgkin lymphoma in China. Pathol Oncol Res. 2011;17(2):369\u201373.","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"4523_CR170","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010200","volume":"18","author":"A Jorapur","year":"2022","unstructured":"Jorapur A, Marshall LA, Jacobson S, Xu M, Marubayashi S, Zibinsky M, et al. EBV+ tumors exploit tumor cell-intrinsic and-extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22. PLoS Pathog. 2022;18(1):e1010200.","journal-title":"PLoS Pathog"},{"issue":"9","key":"4523_CR171","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1182\/blood.V96.9.3133","volume":"96","author":"T Spieker","year":"2000","unstructured":"Spieker T, Kurth J, K\u00fcppers R, Rajewsky K, Br\u00e4uninger A, Hansmann M-L. Molecular single-cell analysis of the clonal relationship of small Epstein-Barr virus\u2013infected cells and Epstein-Barr virus\u2013harboring Hodgkin and Reed\/Sternberg cells in Hodgkin disease. Blood. 2000;96(9):3133\u20138.","journal-title":"Blood"},{"issue":"Suppl 7","key":"4523_CR172","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-018-0437-8","volume":"11","author":"LAE Nagai","year":"2019","unstructured":"Nagai LAE, Park SJ, Nakai K. Analyzing the 3D chromatin organization coordinating with gene expression regulation in B-cell lymphoma. BMC Med Genomics. 2019;11(Suppl 7):127.","journal-title":"BMC Med Genomics"},{"issue":"4","key":"4523_CR173","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/path.4198","volume":"230","author":"M Vockerodt","year":"2013","unstructured":"Vockerodt M, Wei W, Nagy E, Prouzova Z, Schrader A, Kube D, et al. Suppression of the LMP2A target gene, EGR-1, protects Hodgkin\u2019s lymphoma cells from entry to the EBV lytic cycle. J Pathol. 2013;230(4):399\u2013409.","journal-title":"J Pathol"},{"issue":"5","key":"4523_CR174","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/jmv.25381","volume":"91","author":"R Incrocci","year":"2019","unstructured":"Incrocci R, McAloon J, Montesano M, Bardahl J, Vagvala S, Stone A, et al. Epstein-Barr virus LMP2A utilizes Syk and PI3K to activate NF-kappaB in B-cell lymphomas to increase MIP-1alpha production. J Med Virol. 2019;91(5):845\u201355.","journal-title":"J Med Virol"},{"issue":"44","key":"4523_CR175","doi-asserted-by":"publisher","first-page":"15730","DOI":"10.1073\/pnas.0402135101","volume":"101","author":"S Stewart","year":"2004","unstructured":"Stewart S, Dawson CW, Takada K, Curnow J, Moody CA, Sixbey JW, et al. Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kappaB transcription factor pathway. Proc Natl Acad Sci U S A. 2004;101(44):15730\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4523_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2021.198399","volume":"297","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Xiao H, Sun L, Zhang Y, Liu S, Luo B. LMP2A suppresses the role of AHR pathway through ERK signal pathway in EBV-associated gastric cancer. Virus Res. 2021;297:198399.","journal-title":"Virus Res"},{"issue":"23","key":"4523_CR177","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2017-07-796821","volume":"130","author":"K Fish","year":"2017","unstructured":"Fish K, Sora RP, Schaller SJ, Longnecker R, Ikeda M. EBV latent membrane protein 2A orchestrates p27(kip1) degradation via Cks1 to accelerate MYC-driven lymphoma in mice. Blood. 2017;130(23):2516\u201326.","journal-title":"Blood"},{"key":"4523_CR178","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.virol.2015.05.007","volume":"484","author":"AD Pal","year":"2015","unstructured":"Pal AD, Banerjee S. Epstein\u2013Barr virus latent membrane protein 2A mediated activation of Sonic Hedgehog pathway induces HLA class Ia downregulation in gastric cancer cells. Virology. 2015;484:22\u201332.","journal-title":"Virology"},{"issue":"14","key":"4523_CR179","first-page":"2228","volume":"125","author":"JH Lin","year":"2015","unstructured":"Lin JH, Lin JY, Chou YC, Chen MR, Yeh TH, Lin CW, et al. Epstein-Barr virus LMP2A suppresses MHC class II expression by regulating the B-cell transcription factors E47 and PU. 1. Blood J Am Soc Hematol. 2015;125(14):2228\u201338.","journal-title":"Blood J Am Soc Hematol"},{"key":"4523_CR180","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.canlet.2021.11.031","volume":"526","author":"Y Du","year":"2022","unstructured":"Du Y, Zhang J-y, Gong L-p, Feng Z-y, Wang D, Pan Y-h, et al. Hypoxia-induced ebv-circLMP2A promotes angiogenesis in EBV-associated gastric carcinoma through the KHSRP\/VHL\/HIF1\u03b1\/VEGFA pathway. Cancer Lett. 2022;526:259\u201372.","journal-title":"Cancer Lett"},{"issue":"1","key":"4523_CR181","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1182\/blood-2006-11-059881","volume":"111","author":"JR Flavell","year":"2008","unstructured":"Flavell JR, Baumforth KR, Wood VH, Davies GL, Wei W, Reynolds GM, et al. Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood. 2008;111(1):292\u2013301.","journal-title":"Blood"},{"issue":"19","key":"4523_CR182","doi-asserted-by":"publisher","first-page":"11166","DOI":"10.1128\/JVI.01785-14","volume":"88","author":"S Mansouri","year":"2014","unstructured":"Mansouri S, Pan Q, Blencowe BJ, Claycomb JM, Frappier L. Epstein-barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer. J Virol. 2014;88(19):11166\u201377.","journal-title":"J Virol"},{"issue":"1","key":"4523_CR183","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2353\/ajpath.2008.070845","volume":"173","author":"KR Baumforth","year":"2008","unstructured":"Baumforth KR, Birgersdotter A, Reynolds GM, Wei W, Kapatai G, Flavell JR, et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin\u2019s lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol. 2008;173(1):195\u2013204.","journal-title":"Am J Pathol"},{"issue":"28","key":"4523_CR184","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1038\/sj.onc.1210496","volume":"26","author":"VH Wood","year":"2007","unstructured":"Wood VH, O\u2019Neil JD, Wei W, Stewart SE, Dawson CW, Young LS. Epstein-barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGFbeta signaling pathways. Oncogene. 2007;26(28):4135\u201347.","journal-title":"Oncogene"},{"issue":"9","key":"4523_CR185","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1080\/14737140.2021.1918548","volume":"21","author":"PS Pezeshki","year":"2021","unstructured":"Pezeshki PS, Eskian M, Hamblin MR, Rezaei N. Immune checkpoint inhibition in classical hodgkin lymphoma. Expert Rev Anticancer Ther. 2021;21(9):1003\u201316.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6702","key":"4523_CR186","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade8520","volume":"384","author":"J Zak","year":"2024","unstructured":"Zak J, Pratumchai I, Marro BS, Marquardt KL, Zavareh RB, Lairson LL, et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science. 2024;384(6702):eade8520.","journal-title":"Science"},{"issue":"6","key":"4523_CR187","doi-asserted-by":"publisher","first-page":"537","DOI":"10.14639\/0392-100X-N1527","volume":"41","author":"IE Hotoboc","year":"2021","unstructured":"Hotoboc IE, Fudulu A, Grigore R, Bertesteanu S, Huica I, Iancu IV, et al. The association between lncRNA H19 and EZH2 expression in patients with EBV-positive laryngeal carcinoma. Acta Otorhinolaryngol Ital. 2021;41(6):537.","journal-title":"Acta Otorhinolaryngol Ital"},{"issue":"22","key":"4523_CR188","doi-asserted-by":"publisher","first-page":"10778","DOI":"10.1111\/jcmm.16992","volume":"25","author":"M Hayun","year":"2021","unstructured":"Hayun M, Szwarcwort M, Rosenberg D, Sahar D, Ofran Y. Spontaneous arising of a lymphoblastoid B-cell line harbouring a pre-leukemic DNMT3A mutation in acute myeloid leukaemia cell culture. J Cell Mol Med. 2021;25(22):10778\u201382.","journal-title":"J Cell Mol Med"},{"issue":"10","key":"4523_CR189","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1182\/blood.2023021050","volume":"142","author":"CY Cheah","year":"2023","unstructured":"Cheah CY. Pembrolizumab: a key for some, but not all, HL. Blood. 2023;142(10):861\u20132.","journal-title":"Blood"},{"key":"4523_CR190","doi-asserted-by":"publisher","first-page":"S373","DOI":"10.1016\/S2152-2650(21)01854-1","volume":"21","author":"S Ansell","year":"2021","unstructured":"Ansell S, Br\u00f6ckelmann P, von Keudell G, Lee HJ, Santoro A, Zinzani PL, et al. HL-398: five-year overall survival from the CheckMate 205 study of nivolumab for relapsed or refractory (R\/R) classical Hodgkin lymphoma (cHL). Clin Lymphoma Myeloma Leuk. 2021;21:S373\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"4523_CR191","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1080\/10428194.2018.1512709","volume":"60","author":"Y-F Chen","year":"2019","unstructured":"Chen Y-F, Chang C-H, Huang Z-N, Su Y-C, Chang S-J, Jan J-S. The JAK inhibitor antcin H exhibits direct anticancer activity while enhancing chemotherapy against LMP1-expressed lymphoma. Leuk Lymphoma. 2019;60(5):1193\u2013203.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"4523_CR192","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.3324\/haematol.2021.278301","volume":"106","author":"M Kim","year":"2021","unstructured":"Kim M, Lee JO, Koh J, Kim TM, Lee JY, Jeon YK, et al. A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. Haematologica. 2021;106(8):2277\u201380.","journal-title":"Haematologica"},{"issue":"32","key":"4523_CR193","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020;38(32):3794\u2013804.","journal-title":"J Clin Oncol"},{"key":"4523_CR194","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.656364","volume":"12","author":"K Khalaf","year":"2021","unstructured":"Khalaf K, Hana D, Chou JT, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front Immunol. 2021;12:656364.","journal-title":"Front Immunol"},{"issue":"2","key":"4523_CR195","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0092-8674(87)90556-3","volume":"49","author":"L Lombardi","year":"1987","unstructured":"Lombardi L, Newcomb EW, Dalla-Favera R. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. Cell. 1987;49(2):161\u201370.","journal-title":"Cell"},{"issue":"9","key":"4523_CR196","first-page":"3031","volume":"109","author":"G Martire","year":"2024","unstructured":"Martire G, Lovisa F, Carraro E, Rizzato D, Cesaro S, Mura RM, et al. TP53 DNA binding domain mutational status and rituximab-based treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification. Haematologica. 2024;109(9):3031.","journal-title":"Haematologica"},{"issue":"4","key":"4523_CR197","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.hoc.2019.04.001","volume":"33","author":"R Alsharif","year":"2019","unstructured":"Alsharif R, Dunleavy K. Burkitt lymphoma and other high-grade B-cell lymphomas with or without MYC, BCL2, and\/or BCL6 rearrangements. Hematol Oncol Clin North Am. 2019;33(4):587\u201396.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"39","key":"4523_CR198","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/jncimonographs\/lgn020","volume":"2008","author":"JE Guikema","year":"2008","unstructured":"Guikema JE, Schuuring E, Kluin PM. Structure and consequences of IGH switch breakpoints in Burkitt lymphoma. J Natl Cancer Inst Monogr. 2008;2008(39):32\u20136.","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"10","key":"4523_CR199","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1002\/1097-0142(19830515)51:10<1777::AID-CNCR2820511003>3.0.CO;2-E","volume":"51","author":"DP Burkitt","year":"1983","unstructured":"Burkitt DP. Charles S. Mott award. The discovery of Burkitt\u2019s lymphoma. Cancer. 1983;51(10):1777\u201386.","journal-title":"Cancer"},{"issue":"12","key":"4523_CR200","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(04)01650-X","volume":"5","author":"C den Van Bosch","year":"2004","unstructured":"den Van Bosch C. Is endemic Burkitt\u2019s lymphoma an alliance between three infections and a tumour promoter? Lancet Oncol. 2004;5(12):738\u201346.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4523_CR201","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08880018.2020.1871452","volume":"38","author":"ES d\u2019Amore","year":"2021","unstructured":"d\u2019Amore ES, Mainardi C, Mussolin L, Carraro E, Alaggio R, Lazzari E, et al. Histiocytic sarcoma arising in a child affected by Burkitt lymphoma, with t (8; 14)(q24; q32) positivity in both tumors. Pediatr Hematol Oncol. 2021;38(1):1\u20137.","journal-title":"Pediatr Hematol Oncol"},{"key":"4523_CR202","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cancergen.2017.11.007","volume":"220","author":"D Minakata","year":"2018","unstructured":"Minakata D, Sato K, Ikeda T, Toda Y, Ito S, Mashima K, et al. A leukemic double-hit follicular lymphoma associated with a complex variant translocation, t(8;14;18)(q24;q32;q21), involving BCL2, MYC, and IGH. Cancer Genet. 2018;220:44\u20138.","journal-title":"Cancer Genet"},{"issue":"1","key":"4523_CR203","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/ajcp\/aqx139","volume":"149","author":"B Grygalewicz","year":"2018","unstructured":"Grygalewicz B, Woroniecka R, Rymkiewicz G, Rygier J, Borkowska K, Kotyl A, et al. The 11q-gain\/loss aberration occurs recurrently in MYC-negative Burkitt-like lymphoma with 11q aberration, as well as MYC-positive Burkitt lymphoma and MYC-positive high-grade B-cell lymphoma, NOS. Am J Clin Pathol. 2018;149(1):17\u201328.","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"4523_CR204","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03122-2","volume":"23","author":"Y Li","year":"2023","unstructured":"Li Y, Liu Y, Yang K, Jin L, Yang J, Huang S, et al. Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-cell lymphoma treated with CAR-T cell therapy. Cancer Cell Int. 2023;23(1):281.","journal-title":"Cancer Cell Int"},{"key":"4523_CR205","volume-title":"Impact of ID3, TCF3 and CCND3 mutations in burkitt lymphoma: mutation profiles and clinical impact","author":"MT Souza","year":"2019","unstructured":"Souza MT, Alves PD, Pinto LW, Matos RR, Liehr T, Land MG, et al. Impact of ID3, TCF3 and CCND3 mutations in burkitt lymphoma: mutation profiles and clinical impact. Cusco: INCA; 2019."},{"issue":"3","key":"4523_CR206","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41375-019-0628-0","volume":"34","author":"F Gehringer","year":"2020","unstructured":"Gehringer F, Weissinger SE, Moller P, Wirth T, Ushmorov A. Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma. Leukemia. 2020;34(3):857\u201371.","journal-title":"Leukemia"},{"issue":"3","key":"4523_CR207","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cell.2020.12.022","volume":"184","author":"J Dheekollu","year":"2021","unstructured":"Dheekollu J, Wiedmer A, Ayyanathan K, Deakyne JS, Messick TE, Lieberman PM. Cell-cycle-dependent EBNA1-DNA crosslinking promotes replication termination at oriP and viral episome maintenance. Cell. 2021;184(3):643-654. e613.","journal-title":"Cell"},{"issue":"4","key":"4523_CR208","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10040109","volume":"10","author":"JB Wilson","year":"2018","unstructured":"Wilson JB, Manet E, Gruffat H, Busson P, Blondel M, Fahraeus R. EBNA1: oncogenic activity, immune evasion and biochemical functions provide targets for novel therapeutic strategies against Epstein-Barr virus- associated cancers. Cancers (Basel). 2018;10(4):109.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"4523_CR209","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012052","volume":"5","author":"R Sompallae","year":"2010","unstructured":"Sompallae R, Callegari S, Kamranvar SA, Masucci MG. Transcription profiling of Epstein-Barr virus nuclear antigen (EBNA)-1 expressing cells suggests targeting of chromatin remodeling complexes. PLoS ONE. 2010;5(8):e12052.","journal-title":"PLoS ONE"},{"issue":"5","key":"4523_CR210","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1158\/1541-7786.MCR-16-0305","volume":"15","author":"Y Kaymaz","year":"2017","unstructured":"Kaymaz Y, Oduor CI, Yu H, Otieno JA, Ong\u2019echa JM, Moormann AM, et al. Comprehensive transcriptome and mutational profiling of endemic Burkitt lymphoma reveals EBV type-specific differences. Mol Cancer Res. 2017;15(5):563\u201376.","journal-title":"Mol Cancer Res"},{"issue":"15","key":"4523_CR211","doi-asserted-by":"publisher","first-page":"8225","DOI":"10.1128\/JVI.00411-07","volume":"81","author":"HJ Kwun","year":"2007","unstructured":"Kwun HJ, Da Silva SR, Shah IM, Blake N, Moore PS, Chang Y. Kaposi\u2019s sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mimics Epstein-Barr virus EBNA1 immune evasion through central repeat domain effects on protein processing. J Virol. 2007;81(15):8225\u201335.","journal-title":"J Virol"},{"issue":"4","key":"4523_CR212","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1172\/JCI22053","volume":"114","author":"T Fu","year":"2004","unstructured":"Fu T, Voo KS, Wang RF. Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo. J Clin Invest. 2004;114(4):542\u201350.","journal-title":"J Clin Invest"},{"key":"4523_CR213","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/ijc.24014","volume":"124","author":"AM Moormann","year":"2009","unstructured":"Moormann AM, Heller KN, Chelimo K, Embury P, Ploutz-Snyder R, Otieno JA, et al. Children with endemic Burkitt lymphoma are deficient in EBNA1-specific. Int J Cancer. 2009;124:1721\u20136.","journal-title":"Int J Cancer"},{"issue":"1","key":"4523_CR214","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00432-005-0036-x","volume":"132","author":"M Hong","year":"2006","unstructured":"Hong M, Murai Y, Kutsuna T, Takahashi H, Nomoto K, Cheng CM, et al. Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt\u2019s lymphoma cells. J Cancer Res Clin Oncol. 2006;132(1):1\u20138.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"19","key":"4523_CR215","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.7150\/thno.26823","volume":"8","author":"L Jiang","year":"2018","unstructured":"Jiang L, Xie C, Lung HL, Lo KW, Law GL, Mak NK, et al. EBNA1-targeted inhibitors: novel approaches for the treatment of Epstein-Barr virus-associated cancers. Theranostics. 2018;8(19):5307\u201319.","journal-title":"Theranostics"},{"key":"4523_CR216","first-page":"159","volume-title":"Precision molecular pathology of aggressive B-cell lymphomas","author":"S Gong","year":"2024","unstructured":"Gong S. Precision medicine in burkitt and burkitt-like lymphomas. In: Gong S, editor. Precision molecular pathology of aggressive B-cell lymphomas. Cham: Springer; 2024. p. 159\u201378."},{"issue":"12","key":"4523_CR217","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167841","volume":"11","author":"E Parsons","year":"2016","unstructured":"Parsons E, Otieno JA, Ong\u2019echa JM, Nixon CE, Vulule J, Munz C, et al. Regulatory t cells in endemic Burkitt lymphoma patients are associated with poor outcomes: a prospective, longitudinal study. PLoS ONE. 2016;11(12):e0167841.","journal-title":"PLoS ONE"},{"issue":"6suppl","key":"4523_CR218","doi-asserted-by":"publisher","first-page":"712","DOI":"10.21873\/cgp.20418","volume":"20","author":"Y Lee","year":"2023","unstructured":"Lee Y, Nam S. Network and computational drug repurposing analysis for c-Myc inhibition in Burkitt lymphoma. Cancer Genomics Proteomics. 2023;20(6suppl):712\u201322.","journal-title":"Cancer Genomics Proteomics"},{"issue":"1","key":"4523_CR219","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09275-z","volume":"22","author":"X Zhang","year":"2022","unstructured":"Zhang X, Wu Y, Sun X, Cui Q, Bai X, Dong G, et al. The PI3K\/AKT\/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis. BMC Cancer. 2022;22(1):190.","journal-title":"BMC Cancer"},{"issue":"2","key":"4523_CR220","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41388-020-01532-4","volume":"40","author":"A Yoshida","year":"2021","unstructured":"Yoshida A, Choi J, Jin HR, Li Y, Bajpai S, Qie S, et al. Fbxl8 suppresses lymphoma growth and hematopoietic transformation through degradation of cyclin D3. Oncogene. 2021;40(2):292\u2013306.","journal-title":"Oncogene"},{"issue":"5","key":"4523_CR221","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000563","volume":"5","author":"F Nguyen-Khac","year":"2021","unstructured":"Nguyen-Khac F, Bouzy S, Roos-Weil D, Bravetti C, Maillon A, Diop M, et al. Acquisition of TCF3 and CCND3 mutations and transformation to Burkitt lymphoma in a case of B-cell prolymphocytic leukemia. Hemasphere. 2021;5(5):e563.","journal-title":"Hemasphere"},{"key":"4523_CR222","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.114009","volume":"229","author":"F Ran","year":"2022","unstructured":"Ran F, Liu Y, Wang C, Xu Z, Zhang Y, Liu Y, et al. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. Eur J Med Chem. 2022;229:114009.","journal-title":"Eur J Med Chem"},{"issue":"3","key":"4523_CR223","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1182\/bloodadvances.2021004557","volume":"6","author":"Y Liu","year":"2022","unstructured":"Liu Y, Deng B, Hu B, Zhang W, Zhu Q, Liu Y, et al. Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory\/relapsed Burkitt lymphoma. Blood Adv. 2022;6(3):717\u201330.","journal-title":"Blood Adv"},{"issue":"8","key":"4523_CR224","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1007\/s00262-021-02850-6","volume":"70","author":"X Zhou","year":"2021","unstructured":"Zhou X, Ge T, Li T, Huang L, Cao Y, Xiao Y, et al. CAR19\/22 t cell therapy in adult refractory Burkitt\u2019s lymphoma. Cancer Immunol Immunother. 2021;70(8):2379\u201384.","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"4523_CR225","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1080\/10428194.2022.2076853","volume":"63","author":"SJ Seitter","year":"2022","unstructured":"Seitter SJ, McClelland PH, Ahlman MA, Goff SL, Yang JC, McIntyre L, et al. Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience. Leuk Lymphoma. 2022;63(10):2469\u201373.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"4523_CR226","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1016\/j.clml.2024.02.007","volume":"24","author":"S Yamshon","year":"2024","unstructured":"Yamshon S, Gribbin C, Alhomoud M, Chokr N, Chen Z, Demetres M, et al. Safety and toxicity profiles of CAR T cell therapy in non-Hodgkin lymphoma: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2024;24(6):e235-e256 e232.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"16","key":"4523_CR227","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1021\/acschemneuro.1c00350","volume":"12","author":"S Jakhmola","year":"2021","unstructured":"Jakhmola S, Jonniya NA, Sk MF, Rani A, Kar P, Jha HC. Identification of potential inhibitors against Epstein-Barr Virus Nuclear Antigen 1 (EBNA1): an insight from docking and molecular dynamic simulations. ACS Chem Neurosci. 2021;12(16):3060\u201372.","journal-title":"ACS Chem Neurosci"},{"issue":"22","key":"4523_CR228","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225687","volume":"13","author":"G Stewart","year":"2021","unstructured":"Stewart G, Chantry A, Lawson M. The use of oncolytic viruses in the treatment of multiple myeloma. Cancers (Basel). 2021;13(22):5687.","journal-title":"Cancers (Basel)"},{"key":"4523_CR229","doi-asserted-by":"publisher","DOI":"10.1017\/pcm.2023.1","volume":"1","author":"C Chamba","year":"2023","unstructured":"Chamba C, Mbulaiteye SM, Balandya E, Schuh A. Clinical application of circulating cell-free lymphoma DNA for fast and precise diagnosis of Burkitt lymphoma: precision medicine for sub-Saharan Africa. Cambridge Prisms Precision Med. 2023;1:e13.","journal-title":"Cambridge Prisms Precision Med"},{"issue":"1","key":"4523_CR230","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41375-024-02431-3","volume":"39","author":"C Corinaldesi","year":"2025","unstructured":"Corinaldesi C, Holmes AB, Martire G, Tosato A, Rizzato D, Lovisa F, et al. Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance. Leukemia. 2025;39(1):189\u201398.","journal-title":"Leukemia"},{"issue":"44","key":"4523_CR231","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.18632\/oncotarget.27785","volume":"11","author":"N Lodhi","year":"2020","unstructured":"Lodhi N, Tun M, Nagpal P, Inamdar AA, Ayoub NM, Siyam N, et al. Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine. Oncotarget. 2020;11(44):4045\u201373.","journal-title":"Oncotarget"},{"issue":"6","key":"4523_CR232","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.3324\/haematol.2018.215053","volume":"104","author":"M Granai","year":"2019","unstructured":"Granai M, Ambrosio MR, Akarca A, Mundo L, Vergoni F, Santi R, et al. Role of Epstein-Barr virus in transformation of follicular lymphoma to diffuse large B-cell lymphoma: a case report and review of the literature. Haematologica. 2019;104(6):e269\u201373.","journal-title":"Haematologica"},{"issue":"5","key":"4523_CR233","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.pathol.2021.09.009","volume":"54","author":"MH Nam","year":"2022","unstructured":"Nam MH, Hsieh YY, Chen BJ. EBV-positive low-grade follicular lymphoma transforming to EBV-negative high-grade B-cell lymphoma with MYC and BCL2 rearrangements. Pathology. 2022;54(5):634\u20136.","journal-title":"Pathology"},{"issue":"1","key":"4523_CR234","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/(SICI)1096-8652(199605)52:1<21::AID-AJH4>3.0.CO;2-8","volume":"52","author":"K Ohshima","year":"1996","unstructured":"Ohshima K, Suzumiya J, Tasiro K, Mukai Y, Tanaka T, Kato A, et al. Epstein-Barr virus infection and associated products (LMP, EBNA2, vIL-10) in nodal non-Hodgkin\u2019s lymphoma of human immunodeficiency virus-negative Japanese. Am J Hematol. 1996;52(1):21\u20138.","journal-title":"Am J Hematol"},{"issue":"11","key":"4523_CR235","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15113046","volume":"15","author":"EH Ahmed","year":"2023","unstructured":"Ahmed EH, Lustberg M, Hale C, Sloan S, Mao C, Zhang X, et al. Follicular helper and regulatory T cells drive the development of spontaneous Epstein-Barr Virus lymphoproliferative disorder. Cancers (Basel). 2023;15(11):3046.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4523_CR236","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0814-6","volume":"12","author":"B Li","year":"2019","unstructured":"Li B, Chng WJ. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications. J Hematol Oncol. 2019;12(1):118.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"4523_CR237","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1158\/1078-0432.CCR-18-1153","volume":"25","author":"F Desmots","year":"2019","unstructured":"Desmots F, Roussel M, Pangault C, Llamas-Gutierrez F, Pastoret C, Guiheneuf E, et al. Pan-HDAC inhibitors restore PRDM1 response to IL21 in CREBBP-mutated follicular lymphoma. Clin Cancer Res. 2019;25(2):735\u201346.","journal-title":"Clin Cancer Res"},{"key":"4523_CR238","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2023-173638","volume":"142","author":"Y Ito","year":"2023","unstructured":"Ito Y, Shimono J, Kawamoto K, Hatanaka KC, Kogure Y, Koya J, et al. TP53 and CDKN2A alterations define a poor prognostic subgroup in patients with nodal T-follicular helper cell lymphoma. Blood. 2023;142:1630.","journal-title":"Blood"},{"issue":"5","key":"4523_CR239","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11899-019-00541-9","volume":"14","author":"Y Liu","year":"2019","unstructured":"Liu Y, Gonzalez Y, Amengual JE. Chromatin-remodeled state in lymphoma. Curr Hematol Malig Rep. 2019;14(5):439\u201350.","journal-title":"Curr Hematol Malig Rep"},{"issue":"20","key":"4523_CR240","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14204972","volume":"14","author":"F Gallardo","year":"2022","unstructured":"Gallardo F, Pujol RM. Genetics abnormalities with clinical impact in primary cutaneous lymphomas. Cancers (Basel). 2022;14(20):4972.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"4523_CR241","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0668-9","volume":"9","author":"S Bhattacharjee","year":"2018","unstructured":"Bhattacharjee S, Bose P, Patel K, Roy SG, Gain C, Gowda H, et al. Transcriptional and epigenetic modulation of autophagy promotes EBV oncoprotein EBNA3C induced B-cell survival. Cell Death Dis. 2018;9(6):605.","journal-title":"Cell Death Dis"},{"issue":"1","key":"4523_CR242","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-71210-y","volume":"14","author":"IJ Moon","year":"2024","unstructured":"Moon IJ, Won CH, Chang SE, Park CS, Yoon DH, Song SY, et al. Prevalence, clinical features, and survival outcome trends of 627 patients with primary cutaneous lymphoma over 29 years: a retrospective review from single tertiary center in Korea. Sci Rep. 2024;14(1):20118.","journal-title":"Sci Rep"},{"issue":"4","key":"4523_CR243","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/modpathol.2016.214","volume":"30","author":"N Mackrides","year":"2017","unstructured":"Mackrides N, Campuzano-Zuluaga G, Maque-Acosta Y, Moul A, Hijazi N, Ikpatt FO, et al. Epstein-Barr virus-positive follicular lymphoma. Mod Pathol. 2017;30(4):519\u201329.","journal-title":"Mod Pathol"},{"issue":"3","key":"4523_CR244","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/00000478-199603000-00008","volume":"20","author":"TW Shek","year":"1996","unstructured":"Shek TW, Ho FC, Ng IO, Chan AC, Ma L, Srivastava G. Follicular dendritic cell tumor of the liver. Evidence for an Epstein-Barr virus-related clonal proliferation of follicular dendritic cells. Am J Surg Pathol. 1996;20(3):313\u201324.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"4523_CR245","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1046\/j.1365-2141.2001.02579.x","volume":"112","author":"E Orlandi","year":"2001","unstructured":"Orlandi E, Paulli M, Viglio A, Pagnucco G, Riboni R, Baldanti F, et al. Epstein-Barr virus-positive aggressive lymphoma as a consequence of immunosuppression after multiple salvage treatments for follicular lymphoma. Br J Haematol. 2001;112(2):373\u20136.","journal-title":"Br J Haematol"},{"issue":"1","key":"4523_CR246","volume":"2024","author":"S Raychaudhuri","year":"2024","unstructured":"Raychaudhuri S, Dong ZM, Knowles S, Graf S. EBV-positive classic Hodgkin lymphoma and primary nodal T-cell\/NK-cell lymphoma arising in the background of follicular lymphoma. Case Rep Hematol. 2024;2024(1):8810646.","journal-title":"Case Rep Hematol"},{"issue":"9","key":"4523_CR247","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/j.1349-7006.2003.tb01518.x","volume":"94","author":"Y Maesako","year":"2003","unstructured":"Maesako Y, Uchiyama T, Ohno H. Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt\u2019s lymphoma and de novo diffuse large B-cell lymphoma. Cancer Sci. 2003;94(9):774\u201381.","journal-title":"Cancer Sci"},{"issue":"16","key":"4523_CR248","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1158\/0008-5472.CAN-15-0589","volume":"76","author":"KS Le","year":"2016","unstructured":"Le KS, Thibult ML, Just-Landi S, Pastor S, Gondois-Rey F, Granjeaud S, et al. Follicular b lymphomas generate regulatory T cells via the ICOS\/ICOSL pathway and are susceptible to treatment by anti-ICOS\/ICOSL therapy. Cancer Res. 2016;76(16):4648\u201360.","journal-title":"Cancer Res"},{"issue":"13","key":"4523_CR249","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMra032015","volume":"350","author":"DA Thorley-Lawson","year":"2004","unstructured":"Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004;350(13):1328\u201337.","journal-title":"N Engl J Med"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04523-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04523-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04523-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:07:11Z","timestamp":1772582831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04523-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":249,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4523"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04523-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"25 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"387"}}